We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · March 18, 2021

Curative Potential of R-CEOP in Patients With Diffuse Large B-Cell Lymphoma

Blood advances

 

Additional Info

Disclosure statements are available on the authors' profiles:

Blood advances
Long-Term Outcomes of R-CEOP Show Curative Potential in Patients With DLBCL and a Contraindication to Anthracyclines
Blood Adv 2021 Mar 09;5(5)1483-1489, AA Moccia, K Schaff, C Freeman, PJ Hoskins, RJ Klasa, KJ Savage, TN Shenkier, RD Gascoyne, JM Connors, LH Sehn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading